Aptevo to Present Preclinical Data

Aptevo Therapeutics, a biotechnology company developing oncology and hematology treatments, said Tuesday it will present preclinical data for new bispecific antibody candidates at a medical conference in April.

“Based on Aptevo’s proprietary ADAPTIR protein therapeutic platform, the company’s latest bispecific candidates targeting CD123 were designed to redirect T-cell cytotoxicity to CD123-expressing tumors cells, a cell surface receptor highly expressed in several hematological malignancies,” the company said in a statement.

Results to be presented at the conference will relate to optimized lead candidates, APVO436 and APVO437, in preclinical models of acute myeloid leukemia, the company said. The shares rose 2.2% on Tuesday morning.

Related posts

Leave a Comment